Latest / Injectable & Ophthalmic Insights / Third Party Manufacturing in Pharma Why Most Brands Don't Own a Factory Anymore

Transcript

Third Party Manufacturing in Pharma Why Most Brands Don't Own a Factory Anymore · Injectable & Ophthalmic Insights

• 0:00
  Speaker 1: Picture your bathroom medicine cabinet right now. Open the mirror.
• 0:04
  Speaker 1: You look at those little boxes and bottles lined up
• 0:07
  Speaker 1: on the shelf. You've got your brand name eye drops,
• 0:10
  Speaker 1: maybe some nasal spray, a box of specialized injections you
• 0:16
  Speaker 1: or maybe a family member might need. And you trust
• 0:20
  Speaker 1: those names. You see the logo and you naturally assume
• 0:23
  Speaker 1: there is this like, massive gleaming laboratory somewhere with that
• 0:27
  Speaker 1: exact logo on the side of the building.
• 0:29
  Speaker 2: Right. Full of scientists.
• 0:30
  Speaker 1: Exactly. Full of scientists in white coats mixing that exact
• 0:33
  Speaker 1: formula just for you. But what if I told you
• 0:36
  Speaker 1: that when you buy a brand name medicine, the company
• 0:39
  Speaker 1: whose name is printed in like big, bold letters on
• 0:42
  Speaker 1: the box, they probably didn't actually make it. Yeah.
• 0:45
  Speaker 2: It is one of the most hidden realities of the
• 0:47
  Speaker 2: modern consumer experience. Honestly, it's entirely out of sight.
• 0:50
  Speaker 1: Yeah.
• 0:51
  Speaker 2: Because we naturally assume a direct product an unbroken line
• 0:56
  Speaker 2: between the name on the package and the factory floor
• 0:58
  Speaker 2: where the chemicals are mixed. Sure. But the modern pharmaceutical industry,
• 1:01
  Speaker 2: that line is, well, it's fractured by design.
• 1:04
  Speaker 1: It's kind of like hiring a Michelin star ghost kitchen.
• 1:07
  Speaker 2: Good way to put it.
• 1:08
  Speaker 1: Yeah, like you don't need to know how to cook,
• 1:10
  Speaker 1: you don't need to buy the expensive commercial ovens, and
• 1:12
  Speaker 1: you certainly don't need to worry about passing the local
• 1:14
  Speaker 1: health inspection. You just come up with this catchy name
• 1:17
  Speaker 1: for the restaurant, build a great app, and the ghost
• 1:20
  Speaker 1: kitchen just, they hand you a perfectly cooked, fully approved
• 1:24
  Speaker 1: meal in a box with your specific logo on it.
• 1:27
  Speaker 2: Exactly.
• 1:29
  Speaker 1: So today, our deep dive is pulling back the curtain
• 1:32
  Speaker 1: on this exact business model within the medical world. We
• 1:35
  Speaker 1: are looking at some incredibly revealing excerpts from a recent
• 1:39
  Speaker 1: industry update. Specifically, we have materials from Injectable and Ophthalmic
• 1:45
  Speaker 1: Insights and a comprehensive 2026 guide on third-party manufacturing. Right.
• 1:51
  Speaker 1: So our mission today is to really understand how the
• 1:53
  Speaker 1: shadow system works, like who is actually making our medicine
• 1:56
  Speaker 1: and why this model completely dominates the industry right now.
• 1:59
  Speaker 2: Right. And the scale of this ghost kitchen model, to
• 2:03
  Speaker 2: borrow your phrase, that is what we really need to
• 2:05
  Speaker 2: establish first.
• 2:06
  Speaker 1: Yeah. How big is it?
• 2:07
  Speaker 2: Well, we aren't talking about a niche workaround for a
• 2:10
  Speaker 2: few small startups trying to save a buck.
• 2:12
  Speaker 1: Right.
• 2:13
  Speaker 2: If we look at the source material, the projections for
• 2:16
  Speaker 2: India's pharmaceutical market in 2026- They value it at 5,20,000
• 2:21
  Speaker 2: crore rupees.
• 2:24
  Speaker 1: Wait, 5,00,000?
• 2:25
  Speaker 2: 20,000 crore.
• 2:26
  Speaker 1: Okay, let's pause and contextualize that for our international listeners
• 2:30
  Speaker 1: who might not be super familiar with the Indian numbering system.
• 2:34
  Speaker 2: Sure.
• 2:34
  Speaker 1: Because a crore is 10 million. Right. And a lac
• 2:37
  Speaker 1: is 100,000. So 5,20,000 crores. I mean, we're talking about...
• 2:43
  Speaker 1: Billions and billions of dollars globally.
• 2:46
  Speaker 2: Yes.
• 2:46
  Speaker 1: It is an astronomical amount of capital flowing through this
• 2:49
  Speaker 1: specific sector.
• 2:50
  Speaker 2: It's an immense amount of capital. Yes. But the critical
• 2:53
  Speaker 2: data point in this report is is how that capital
• 2:56
  Speaker 2: is distributed. OK. A massive I mean, over 50 percent
• 2:59
  Speaker 2: of that entire market is contract or third party manufacturing.
• 3:02
  Speaker 1: Over 50 percent.
• 3:03
  Speaker 2: Over half.
• 3:04
  Speaker 1: Yes. So more often than not, the brand you are
• 3:06
  Speaker 1: buying at the pharmacy is quite literally just a brand.
• 3:10
  Speaker 1: The companies we traditionally think of as, you know, drug makers,
• 3:14
  Speaker 1: they are increasingly just drug marketers and distributors.
• 3:16
  Speaker 2: Exactly. The very architecture of how medicine is brought to
• 3:19
  Speaker 2: the public has fundamentally shifted.
• 3:22
  Speaker 1: Wow. Okay. So if over 50% of the market is outsourced,
• 3:28
  Speaker 1: I think we need to draw a very clear line
• 3:31
  Speaker 1: in the sand here. Like who does what? Because if
• 3:34
  Speaker 1: the brand isn't making the medicine and they are taking
• 3:37
  Speaker 1: home a massive chunk of the profits... What exactly is
• 3:40
  Speaker 1: their role compared to the manufacturer?
• 3:43
  Speaker 2: Well, the division of labor is stark. Yeah. And it's
• 3:46
  Speaker 2: highly specialized.
• 3:46
  Speaker 1: Okay.
• 3:47
  Speaker 2: According to the industry breakdown we are examining, the manufacturer
• 3:50
  Speaker 2: owns the physical factory.
• 3:51
  Speaker 1: Right.
• 3:52
  Speaker 2: They own the heavy, you know, sterilized equipment. They're responsible
• 3:56
  Speaker 2: for procuring all the raw materials.
• 3:58
  Speaker 1: Like the chemicals and stuff.
• 3:59
  Speaker 2: Yes, the actual active pharmaceutical ingredients, the base chemicals. And crucially,
• 4:04
  Speaker 2: they conduct the rigorous quality testing process. Okay. They're the
• 4:08
  Speaker 2: ones physically and chemically creating the medicine.
• 4:11
  Speaker 1: So the brand owner then is strictly handling the branding,
• 4:14
  Speaker 1: the marketing campaigns, the relationships with doctors, and the distribution
• 4:18
  Speaker 1: networks to actually get the physical product onto pharmacy shelves.
• 4:22
  Speaker 2: Precisely.
• 4:23
  Speaker 1: They sell the finished medicines under their own trademark, but
• 4:26
  Speaker 1: they didn't manufacture a single drop of the liquid inside
• 4:29
  Speaker 1: the bottle.
• 4:30
  Speaker 2: That's right. However, we do need to distinguish this from
• 4:34
  Speaker 2: standard consumer goods.
• 4:36
  Speaker 1: What do you mean?
• 4:37
  Speaker 2: Well, you aren't just outsourcing the assembly of plastic toys here.
• 4:40
  Speaker 1: Oh, right, because it's medicine.
• 4:41
  Speaker 2: Exactly. The source text emphasizes that the manufacturer must be
• 4:46
  Speaker 2: licensed and WHO GMP certified.
• 4:49
  Speaker 1: World Health Organization good manufacturing practices.
• 4:52
  Speaker 2: Correct. And this is a rigorous, globally recognized standard of
• 4:56
  Speaker 2: quality control, hygiene consistency, all of that.
• 5:00
  Speaker 1: Yeah.
• 5:00
  Speaker 2: When a facility holds this certification... It means they are
• 5:03
  Speaker 2: tracing every single raw ingredient back to its origin. Wow.
• 5:07
  Speaker 2: They are validating the temperature and humidity of the clean
• 5:10
  Speaker 2: rooms where the chemicals are mixed. Right. They are logging
• 5:12
  Speaker 2: the calibration of the specific machine that caps the bottle.
• 5:16
  Speaker 1: That sounds incredibly intense.
• 5:18
  Speaker 2: It is. The manufacturer is carrying the immense burden of
• 5:22
  Speaker 2: maintaining that certification. They are making the life-saving medicine. But
• 5:26
  Speaker 2: the finished, sterilized, fully compliant product is simply slapped with
• 5:31
  Speaker 2: the brand owner's name at the very end of the line.
• 5:34
  Speaker 1: Wait, wait. If maintaining that level of sterility and certification
• 5:38
  Speaker 1: is so resource intensive, why wouldn't a legacy brand just
• 5:42
  Speaker 1: build its own factory? Like if you are going to
• 5:45
  Speaker 1: be in the highly lucrative business of selling eye drops,
• 5:48
  Speaker 1: wouldn't you want to own the eye drop machine to
• 5:50
  Speaker 1: keep 100% of the profit margin?
• 5:53
  Speaker 2: You'd think so, but the barrier to entry is monumental.
• 5:56
  Speaker 1: Is it just the cost?
• 5:57
  Speaker 2: Mostly, yes. The financial reality of this industry is that
• 6:01
  Speaker 2: Setting up a pharmaceutical manufacturing plant in India costs crores
• 6:05
  Speaker 2: of rupees.
• 6:06
  Speaker 1: Right.
• 6:07
  Speaker 2: We're talking about tens of millions of rupees in pure
• 6:09
  Speaker 2: capital expenditure just to get off the ground.
• 6:12
  Speaker 1: And that's not just, you know, buying a large warehouse
• 6:14
  Speaker 1: and putting some mixing vats inside.
• 6:16
  Speaker 2: Far from it. It requires purchasing appropriate land zoned for
• 6:20
  Speaker 2: chemical manufacturing.
• 6:22
  Speaker 1: The zoning.
• 6:23
  Speaker 2: Yes. It requires installing highly specialized sterile heavy machinery that
• 6:28
  Speaker 2: can handle precise microscopic measurements.
• 6:31
  Speaker 1: Yeah.
• 6:31
  Speaker 2: You have to hire expert scientific staff, chemists, quality assurance managers.
• 6:37
  Speaker 1: That adds up fast.
• 6:38
  Speaker 2: And furthermore, you have to acquire those strict WHO GMP
• 6:42
  Speaker 2: certifications we just mentioned and ensure relentless daily regulatory compliance. Right.
• 6:48
  Speaker 2: The sheer volume of paperwork, ongoing governmental inspections. and quality
• 6:53
  Speaker 2: assurance protocols is staggering.
• 6:55
  Speaker 1: I can imagine.
• 6:56
  Speaker 2: And remember, all of this massive capital expenditure and overhead,
• 7:00
  Speaker 2: it happens before a single pill or drop of medicine
• 7:03
  Speaker 2: is ever shipped to a paying customer.
• 7:04
  Speaker 1: Hold on, though. You're telling me brand owners do this
• 7:06
  Speaker 1: to reduce risk?
• 7:07
  Speaker 2: Yes.
• 7:08
  Speaker 1: Because giving up control of a life-saving chemical formula sounds
• 7:11
  Speaker 1: like the biggest liability a company could possibly take on.
• 7:14
  Speaker 2: I know it sounds.
• 7:15
  Speaker 1: Like, if a batch is tainted, it's the brand's name
• 7:18
  Speaker 1: on the news, not the hidden factory, right? How does
• 7:21
  Speaker 1: outsourcing the literal safety of your product make business sense?
• 7:24
  Speaker 2: I know it sounds totally counterintuitive, but the source text
• 7:28
  Speaker 2: explains why this model actually mitigates the most dangerous risks
• 7:31
  Speaker 2: for a brand owner.
• 7:32
  Speaker 1: How so?
• 7:33
  Speaker 2: By outsourcing to a pre-established, already licensed, and already WHO
• 7:38
  Speaker 2: GMP certified manufacturer, the brand owner entirely bypasses the massive
• 7:44
  Speaker 2: upfront capital risk.
• 7:46
  Speaker 1: Okay.
• 7:46
  Speaker 2: But more importantly... They are outsourcing the crushing burden of compliance.
• 7:51
  Speaker 1: Oh, I see. So the regulatory heat is absorbed by
• 7:54
  Speaker 1: the factory.
• 7:54
  Speaker 2: Exactly. The manufacturer already has the deep institutional expertise. They
• 7:59
  Speaker 2: already have the certified clean rooms operating at peak efficiency.
• 8:03
  Speaker 1: Right.
• 8:04
  Speaker 2: They already have the supply chains for raw materials completely
• 8:07
  Speaker 2: locked in and vetted. They have mastered the literal science
• 8:10
  Speaker 2: of production.
• 8:10
  Speaker 1: So the brand just swoops in.
• 8:12
  Speaker 2: Right. The brand owner simply brings the market demand. If
• 8:15
  Speaker 2: a brand identifies a need in the market, say... They
• 8:18
  Speaker 2: notice a shortage of a specific nasal spray in a
• 8:20
  Speaker 2: particular region. They don't have to spend three years building
• 8:23
  Speaker 2: a factory to meet that need. They leverage the manufacturer's
• 8:26
  Speaker 2: existing fully legal, fully compliant infrastructure to fill that gap rapidly. Okay.
• 8:31
  Speaker 1: That brings up a huge logistical question for me.
• 8:34
  Speaker 2: Okay.
• 8:34
  Speaker 1: If I am a brand owner and I've decided to
• 8:37
  Speaker 1: avoid the nightmare of building a multi-core factory and I
• 8:41
  Speaker 1: want to use a third-party manufacturer.
• 8:44
  Speaker 2: Mm-hmm.
• 8:45
  Speaker 1: How long does it actually take to spin up a
• 8:47
  Speaker 1: new medicine brand from scratch?
• 8:50
  Speaker 2: You'd be surprised.
• 8:50
  Speaker 1: Because in my head, even with an existing factory sourcing
• 8:54
  Speaker 1: chemicals and validating medical products, I mean, that has to
• 8:57
  Speaker 1: take years.
• 8:59
  Speaker 2: The documentation outlines a remarkably fast timeline. It does not
• 9:03
  Speaker 2: take years.
• 9:03
  Speaker 1: Really? No.
• 9:05
  Speaker 2: For a brand new product launch, they outline a 30
• 9:07
  Speaker 2: to 45 day countdown for a first batch.
• 9:11
  Speaker 1: Wait, 30 to 45 days?
• 9:12
  Speaker 2: Yes.
• 9:13
  Speaker 1: From having nothing but a brand name to having a
• 9:15
  Speaker 1: fully manufactured, quality-controlled batch of medicine ready to sell to pharmacies?
• 9:20
  Speaker 2: For the first batch, yes.
• 9:21
  Speaker 1: That's insane.
• 9:22
  Speaker 2: The guide details a very specific step-by-step process that makes
• 9:26
  Speaker 2: as rapid turnaround possible.
• 9:27
  Speaker 1: Okay, walk me through that.
• 9:28
  Speaker 2: So it happens in five distinct phases. Okay. Step one
• 9:31
  Speaker 2: is product selection and quotation. The brand decides exactly which
• 9:35
  Speaker 2: standardized formulation they want to sell, and the manufacturer provides
• 9:38
  Speaker 2: the cost based on volume. Got it. Step two is
• 9:41
  Speaker 2: documentation verification. This ensures all the legal, trademark, and regulatory
• 9:47
  Speaker 2: agreements between the brand and the factory are airtight.
• 9:50
  Speaker 1: Makes sense. You have to get the business and legal
• 9:51
  Speaker 1: frameworks locked down before anyone touches a chemical. Right.
• 9:55
  Speaker 2: Then step three is artwork approval. Okay. Step four is
• 9:59
  Speaker 2: raw material processing. and actual manufacturing.
• 10:02
  Speaker 1: Yeah.
• 10:02
  Speaker 2: And finally, step five is quality control and dispatch. Wait, wait.
• 10:07
  Speaker 1: I need to stop you right there. I have to
• 10:08
  Speaker 1: zero in on step three.
• 10:09
  Speaker 2: Okay.
• 10:09
  Speaker 1: Artwork approval.
• 10:10
  Speaker 2: Yes.
• 10:11
  Speaker 1: Are you telling me that right in the middle of
• 10:13
  Speaker 1: securing highly sensitive chemical raw materials... Mm-hmm. Right before actual
• 10:19
  Speaker 1: laboratory manufacturing and rigorous quality control for life-saving drugs, we
• 10:24
  Speaker 1: pause the entire timeline to approve artwork. Like, we are
• 10:28
  Speaker 1: stopping the presses to make sure the font on the
• 10:30
  Speaker 1: cardboard box looks pretty.
• 10:32
  Speaker 2: I know how it sounds, but it highlights perfectly how
• 10:35
  Speaker 2: the third-party model functions under the surface.
• 10:37
  Speaker 1: Walk me through that, because it sounds absurd to prioritize
• 10:41
  Speaker 1: graphic design over medical procurement.
• 10:43
  Speaker 2: Think about it this way. The factory already knows exactly
• 10:46
  Speaker 2: how to make that specific eyedrop or injection.
• 10:48
  Speaker 1: Okay.
• 10:49
  Speaker 2: They are likely making the exact same chemical formulation for
• 10:54
  Speaker 2: five or ten other brands already. Oh, wow. Yeah, they
• 10:57
  Speaker 2: have the WHO GMP processes for that specific chemical completely
• 11:02
  Speaker 2: locked in. Right. The brand owner isn't inventing a new
• 11:05
  Speaker 2: chemical compound, you know. They are purchasing a standardized formula.
• 11:09
  Speaker 1: Okay, I see where you're going with this.
• 11:11
  Speaker 2: Therefore, the box design, the branding, the colors, the typography,
• 11:15
  Speaker 2: that is quite literally the only unique value the brand
• 11:19
  Speaker 2: owner is adding to the physical product on that assembly line. Wow.
• 11:23
  Speaker 1: So the medicine is essentially a solved problem.
• 11:25
  Speaker 2: Exactly.
• 11:25
  Speaker 1: The chemistry is just copy paste for the factory. So
• 11:27
  Speaker 1: the only thing they actually need from the brand owner
• 11:30
  Speaker 1: before they can hit start on the machines is the
• 11:33
  Speaker 1: digital file of the logo to print on the packaging.
• 11:36
  Speaker 2: You've got it. The artwork is the sole differentiator on
• 11:40
  Speaker 2: the physical factory floor between one brand's order and another
• 11:43
  Speaker 2: brand's order of the exact same medical formulation.
• 11:47
  Speaker 1: That is wild.
• 11:48
  Speaker 2: And the text points out that while this initial setup,
• 11:51
  Speaker 2: including that artwork approval, takes 30 to 45 days, subsequent
• 11:55
  Speaker 2: orders run even faster once the design is finalized and
• 11:58
  Speaker 2: the templates are saved.
• 11:59
  Speaker 1: Okay, so we've discussed the theory, we've looked at the
• 12:02
  Speaker 1: economic forces, and we've walked through the timeline. Now, let's
• 12:05
  Speaker 1: look at a concrete real-world example to kind of anchor
• 12:08
  Speaker 1: this for the listener.
• 12:09
  Speaker 2: Sure.
• 12:10
  Speaker 1: The 2026 Guide provides a specific case study of what
• 12:14
  Speaker 1: a powerhouse third-party manufacturer looks like in practice. Let's talk
• 12:19
  Speaker 1: about Pushkar Pharma.
• 12:20
  Speaker 2: Right, Pushkar Pharma. They serve as the gold standard in
• 12:23
  Speaker 2: this industry update.
• 12:24
  Speaker 1: Yeah.
• 12:24
  Speaker 2: They're not a new disruptive startup. They have an extensive
• 12:28
  Speaker 2: operational history. having been in business since 1993.
• 12:32
  Speaker 1: Which in the pharmaceutical industry, I mean, that means they
• 12:34
  Speaker 1: have weathered decades of changing government regulations.
• 12:37
  Speaker 2: Oh, absolutely.
• 12:38
  Speaker 1: Shifting market demands, massive technological overhauls in manufacturing.
• 12:42
  Speaker 2: Yes, exactly. And the text specifically highlights their facility location
• 12:47
  Speaker 2: in Kala Am.
• 12:48
  Speaker 1: Okay.
• 12:49
  Speaker 2: And returning to the concept of trusting a third party
• 12:51
  Speaker 2: with safety, the guide emphasizes that this is a fully
• 12:55
  Speaker 2: WHO GMP and ISO certified facility. Right. But what really
• 12:59
  Speaker 2: cements them as a powerhouse manufacturer is the sheer breadth
• 13:03
  Speaker 2: of their capabilities, all housed under one single roof.
• 13:06
  Speaker 1: Because they aren't just specializing in one tiny niche of medicine.
• 13:10
  Speaker 2: No, not at all. They cover parenterals, which are injectables,
• 13:13
  Speaker 2: as well as ophthalmic formulations, which are your eye drops.
• 13:16
  Speaker 1: Right.
• 13:16
  Speaker 2: They handle hormonal injections and both nasal and ear drops.
• 13:19
  Speaker 1: Wow.
• 13:20
  Speaker 2: And managing the varying sterile environments, the different specialized bottling lines,
• 13:24
  Speaker 2: and the distinct chemical requirements for that massive variety of
• 13:27
  Speaker 2: products in a single facility... It requires immense operational discipline.
• 13:31
  Speaker 1: I bet. You know, as I was reading through the
• 13:33
  Speaker 1: source material on Pushkar Pharma, I noticed two very specific
• 13:37
  Speaker 1: operational details that seemed almost impossible for an industry this
• 13:41
  Speaker 1: heavily regulated.
• 13:42
  Speaker 2: What were they?
• 13:42
  Speaker 1: First, they offer batch delivery in 48 hours for repeat orders.
• 13:47
  Speaker 1: And second, they offer flexible minimum order quantities.
• 13:50
  Speaker 2: Yeah, those two factors are the true engine of the
• 13:53
  Speaker 2: rapid market growth we discussed at the very beginning of
• 13:55
  Speaker 2: our deep dive.
• 13:56
  Speaker 1: Let's unpack the first one then. Like, how can a
• 13:59
  Speaker 1: facility physically manufacture, test, and dispatch a highly regulated sterile
• 14:05
  Speaker 1: medical product in two days?
• 14:08
  Speaker 2: Well, because for a repeat order, the groundwork is entirely laid.
• 14:11
  Speaker 1: Right.
• 14:12
  Speaker 2: The factory operates with vast, continuous supply chains of base,
• 14:16
  Speaker 2: active pharmaceutical ingredients.
• 14:18
  Speaker 1: Okay.
• 14:18
  Speaker 2: They likely have the standardized base formulas already procured, heavily tested,
• 14:23
  Speaker 2: and perhaps even pre-mixed and staged in sterile vats.
• 14:25
  Speaker 1: Oh, wow. So it's just ready to go.
• 14:27
  Speaker 2: Exactly. When a repeat order comes in, the 48 hours
• 14:31
  Speaker 2: is largely about queuing that validated formula onto the packaging line,
• 14:35
  Speaker 2: running it into your previously approved branded bottles, executing the
• 14:39
  Speaker 2: final quality assurance checks, and putting it on a truck.
• 14:42
  Speaker 1: So the heavy lifting of the chemistry is constantly humming
• 14:45
  Speaker 1: in the background, and the brand is just tapping into
• 14:47
  Speaker 1: that stream on demand. That leads right into the second detail.
• 14:53
  Speaker 1: Flexible minimum order quantities. Right. Because usually the barrier to
• 14:57
  Speaker 1: entry for physical products, especially medicine, is that a factory
• 15:01
  Speaker 1: won't even talk to you unless you are ordering a
• 15:03
  Speaker 1: million units.
• 15:04
  Speaker 2: Typically, yeah.
• 15:04
  Speaker 1: Does this mean someone could basically start a boutique pharma
• 15:07
  Speaker 1: brand just to test the waters of market demand without
• 15:11
  Speaker 1: committing to a massive warehouse full of inventory?
• 15:14
  Speaker 2: The text confirms this explicitly, yes.
• 15:16
  Speaker 1: Wow.
• 15:17
  Speaker 2: They offer flexible minimums specifically to accommodate brands that are
• 15:21
  Speaker 2: still testing products. market demand or operating in highly specific
• 15:26
  Speaker 2: regional niches. It dramatically lowers the barrier to entry. Like
• 15:30
  Speaker 2: if you have a solid distribution network, maybe you own
• 15:32
  Speaker 2: a chain of regional clinics or you have strong relationships
• 15:35
  Speaker 2: with local pharmacies, you can experiment with new product lines
• 15:39
  Speaker 2: with incredibly low financial risk.
• 15:41
  Speaker 1: But again, thinking like a consumer here, if I'm a
• 15:44
  Speaker 1: brand ordering a tiny batch to test the waters, How
• 15:47
  Speaker 1: do I know the factory didn't cut corners on my small,
• 15:50
  Speaker 1: low-priority order? Like, do the safety standards drop when the
• 15:53
  Speaker 1: order size drops?
• 15:54
  Speaker 2: No, absolutely not. The safety is guaranteed by the documentation,
• 15:58
  Speaker 2: regardless of volume. Okay. The source material points out that
• 16:01
  Speaker 2: Pushcar Pharma provides full documentation, including COA certificates, on every
• 16:06
  Speaker 2: single batch dispatched.
• 16:08
  Speaker 1: Let's explain what a COA is for the listener, just
• 16:10
  Speaker 1: to be clear.
• 16:11
  Speaker 2: Good idea. So COA stands for Certificate of Analysis. Right.
• 16:16
  Speaker 2: It is a highly authenticated, legally binding document certifying that
• 16:20
  Speaker 2: the specific batch of medicine meets all the required chemical specifications,
• 16:25
  Speaker 2: purity levels, and safety standards. Okay.
• 16:28
  Speaker 1: So it's like a fingerprint.
• 16:29
  Speaker 2: Exactly. It is essentially the chemical fingerprint of that specific batch.
• 16:33
  Speaker 2: So whether you order 10,000 units or 100,000 units, the
• 16:36
  Speaker 2: standard of chemical analysis and the requirement for that certificate
• 16:39
  Speaker 2: remains absolutely identical.
• 16:41
  Speaker 1: Wow. So it is incredibly safe and astonishingly easy for
• 16:44
  Speaker 1: new brands to experiment in the market.
• 16:46
  Speaker 2: Yes.
• 16:47
  Speaker 1: They don't need to build a factory. They don't need
• 16:48
  Speaker 1: to commit to millions of dollars in upfront inventory. Right.
• 16:52
  Speaker 1: And they receive documented certified proof of safety for every
• 16:56
  Speaker 1: single bottle they sell. It is a completely frictionless entry
• 17:01
  Speaker 1: into the business of selling medicine.
• 17:03
  Speaker 2: Which is exactly why the contract manufacturing segment has captured
• 17:08
  Speaker 2: over 50% of that 5,20,000 crore rupee market.
• 17:13
  Speaker 1: Right.
• 17:13
  Speaker 2: It is an irresistible, highly optimized business model.
• 17:17
  Speaker 1: Yeah.
• 17:17
  Speaker 2: The manufacturer achieves massive economies of scale. By producing baseline
• 17:22
  Speaker 2: chemicals for dozens of brands.
• 17:24
  Speaker 1: And the brands achieve extreme agility by avoiding capital expenditure
• 17:29
  Speaker 1: and focusing entirely on sales. It is a perfectly symbiotic
• 17:33
  Speaker 1: relationship on the business side, but one that the average
• 17:36
  Speaker 1: consumer is entirely blind to when they walk into a store.
• 17:39
  Speaker 2: Entirely.
• 17:40
  Speaker 1: So let's look at the full picture of the journey
• 17:42
  Speaker 1: we've been on today. We started with the illusion of
• 17:45
  Speaker 1: the pharmacy shelf, like this deeply held belief that the
• 17:48
  Speaker 1: trusted name on the box is the wizard behind the
• 17:51
  Speaker 1: curtain physically mixing the chemicals to heal us. And we
• 17:54
  Speaker 1: shattered that illusion with the reality of an industry where
• 17:57
  Speaker 1: the majority of production is outsourced to highly efficient mega factories.
• 18:02
  Speaker 1: We explored the rigid, distinct division of labor. The hidden
• 18:06
  Speaker 1: factory does the rigorous science And the highly visible brand
• 18:09
  Speaker 1: does the sale.
• 18:11
  Speaker 2: Right. We also examine the immense economic gravity that forces
• 18:15
  Speaker 2: this reality into existence.
• 18:17
  Speaker 1: Yeah.
• 18:18
  Speaker 2: Building a WHO GMP certified facility costs tens of millions
• 18:23
  Speaker 2: of rupees and requires navigating an endless labyrinth of compliance
• 18:27
  Speaker 2: and safety protocols.
• 18:28
  Speaker 1: It's just too much.
• 18:29
  Speaker 2: Yeah. So outsourcing allows a brand to bypass that nightmare entirely,
• 18:34
  Speaker 2: going from a mere concept to a finished quality controlled product.
• 18:38
  Speaker 2: in just 30 to 45 days.
• 18:40
  Speaker 1: Incredible. And we saw how this theory operates in the
• 18:42
  Speaker 1: real world with Pushkar Pharma in Kala Am.
• 18:45
  Speaker 2: Exactly.
• 18:46
  Speaker 1: A massive facility operating since 1993, managing everything from injectables
• 18:50
  Speaker 1: to nasal drops under one roof and turning around repeat
• 18:53
  Speaker 1: orders in just 48 hours with flexible minimums and full
• 18:57
  Speaker 1: certificate of analysis documentation. Right. It is an incredibly well-oiled
• 19:01
  Speaker 1: machine that prioritizes speed, safety, and scale.
• 19:04
  Speaker 2: And if we bring this directly back to the listener,
• 19:06
  Speaker 2: This knowledge fundamentally changes how you interact with the medical marketplace.
• 19:10
  Speaker 1: Oh, completely.
• 19:10
  Speaker 2: The next time you are standing at the pharmacy, perhaps
• 19:13
  Speaker 2: feeling stressed or unwell, and you're trying to choose between
• 19:17
  Speaker 2: a premium expensive brand name and a lesser known brand
• 19:20
  Speaker 2: of eye drops sitting right next to it, you now
• 19:23
  Speaker 2: have a completely new lens to view that choice through.
• 19:26
  Speaker 1: Because there is a highly likely chance they both came
• 19:29
  Speaker 1: from the exact same certified third-party factory line.
• 19:33
  Speaker 2: Exactly. They might possess the exact same certificate of analysis.
• 19:37
  Speaker 2: they were likely produced in the exact same sterile room
• 19:40
  Speaker 2: in Kellam. Wow. The only physical difference between the two
• 19:44
  Speaker 2: products is the artwork that was approved in step three,
• 19:47
  Speaker 2: the manufacturing process, and the size of the Wow. It
• 19:40
  Speaker 2: completely upends how we assign value to the things we
• 19:42
  Speaker 2: buy for our health. It really does. Like, we are
• 19:44
  Speaker 2: paying for the brand's ability to design a trustworthy box
• 19:46
  Speaker 2: and distribute the product to our local store, not necessarily
• 19:49
  Speaker 2: their unique medical genius or proprietary science. Right.
• 20:08
  Speaker 1: Which leaves me with a final, slightly unsettling thought to
• 20:11
  Speaker 1: wrap up our deep dive today. If the actual manufacturing,
• 20:14
  Speaker 1: the rigorous quality control, and the chemical formulation of our
• 20:17
  Speaker 1: medicines are completely standardized, heavily certified, and entirely outsourced to
• 20:23
  Speaker 1: these hidden mega factories, does that mean the future success
• 20:27
  Speaker 1: of a pharmaceutical company will rely entirely on marketing algorithms
• 20:31
  Speaker 1: and package design rather than medical science?
• 20:33
  Speaker 2: Wow.
• 20:34
  Speaker 1: Think about that next time you reach for a box
• 20:36
  Speaker 1: in the pharmacy aisle.